Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study

Author summary Why was this study done? A novel SARS-CoV-2 variant emerged in the United Kingdom, B.1.1.7 (known also as Alpha), but the consequences of the introduction of this variant into a new national population are insufficiently understood.The first study objective was to characterize the epidemiology of B.1.1.7 immediately after its introduction into a naive population for this variant.The second study objective was to investigate reinfections with B.1.1.7 and to estimate the efficacy of natural infection against reinfection with this variant. What did the researchers do and find? We investigated the epidemiology of B.1.1.7 using 2 national retrospective cohort studies, mathematical modeling, and other statistical analyses to answer the study's research questions.A sudden, large, and rapidly growing epidemic wave of B.1.1.7 cases commenced shortly after introduction of this variant into Qatar, and findings suggest that B.1.1.7 was approximately 60% more infectious than the original wild-type circulating variants.The efficacy of natural infection against reinfection with B.1.1.7 was estimated at 97.5% (95% CI: 95.7% to 98.6%) among those with a prior PCR-confirmed infection and at 97.0% (95% CI: 92.5% to 98.7%) among those with a prior antibody-positive result. What do these findings mean? Given its infectiousness, the B.1.1.7 variant can spark an epidemic wave once introduced into a naive population, even in the presence of public health restrictions and high levels of natural immunity.Prior infection with a wild-type SARS-CoV-2 variant is associated with strong protection against infection with B.1.1.7, a variant that does not appear to be associated with serious immune evasion. BackgroundThe epidemiology of the SARS-CoV-2 B.1.1.7 (or Alpha) variant is insufficiently understood. This study's objective was to describe the introduction and expansion of this variant in Qatar and to estimate the efficacy of natural infection against reinfection with this variant. Methods and findingsReinfections with the B.1.1.7 variant and variants of unknown status were investigated in a national cohort of 159,003 individuals with prior PCR-confirmed infections and a national cohort of 43,127 antibody-positive individuals. Infections with B.1.1.7 and variants of unknown status were also investigated in a national comparator cohort of 150,106 antibody-negative individuals. B.1.1.7 was first identified in Qatar on 25 December 2020. Sudden, large B.1.1.7 epidemic expansion was observed starting on 18 January 2021, triggering the onset of epidemic's second wave, 7 months after the first wave. B.1.1.7 was about 60% more infectious than the original (wild-type) circulating variants. Among persons with a prior PCR-confirmed infection, the efficacy of natural infection against reinfection was estimated to be 97.5% (95% CI: 95.7% to 98.6%) for B.1.1.7 and 92.2% (95% CI: 90.6% to 93.5%) for variants of unknown status. Among antibody-positive persons, the efficacy of natural infection against reinfection was estimated to be 97.0% (95% CI: 92.5% to 98.7%) for B.1.1.7 and 94.2% (95% CI: 91.8% to 96.0%) for variants of unknown status. A main limitation of this study is assessment of reinfections based on documented PCR-confirmed reinfections, but other reinfections could have occurred and gone undocumented. ConclusionsIn this study, we observed that introduction of B.1.1.7 into a naive population can create a major epidemic wave, but natural immunity in those previously infected was strongly associated with limited incidence of reinfection by B.1.1.7 or other variants.

Automated summary

The novel SARS-CoV-2 variant B.1.1.7 (Alpha) can cause a significant epidemic wave when introduced into a naive population, but individuals with prior infections have strong immunity against reinfection with B.1.1.7.